Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Monoclonal Antibody Therapy COVID-19 Infusion Centers – Provider Referrals

Johns Hopkins Medicine is providing outpatient infusion therapy in Maryland and the District of Columbia for patients with COVID-19.

Find referral information for our infusion therapy sites
The Baltimore Convention Center | Howard County General Hospital | Sibley Memorial Hospital

In Maryland, Johns Hopkins Medicine and the University of Maryland Medical System are operating an outpatient center located at the Baltimore Convention Center. The infusion center administers monoclonal antibody therapies authorized by the U.S. Food and Drug Administration (FDA) under an emergency use authorization (EUA). Referrals are required. Monoclonal antibody therapy helps prevent hospitalization or worsening of symptoms in certain patients with COVID-19, but it may not be appropriate for everyone.

These therapies include:

  • Bamlanivimab (manufactured by Eli Lilly & Co.)

  • A combination of casirivimab and imdevimab, administered simultaneously (known as Regeneron)

  • A combination of bamlanivimab and etesevimab, administered simultaneously (Washington, D.C. & HCGH only)

Monoclonal Antibody Therapy Locations

  • The Baltimore Convention Center COVID-19 Infusion Center is open Monday through Saturday, 8 a.m. to 6 p.m.
  • In addition to the Baltimore Convention Center, Howard County General Hospital is operating an outpatient center in the medical tent outside the hospital’s emergency department entrance. The clinic is for adult patients and is open Tuesday, Wednesday and Friday, 8 a.m. to 6:30 p.m. 
  • In Washington, D.C., Sibley Memorial Hospital is operating an outpatient clinic in the emergency department. Appointments require a referral from a Sibley Memorial Hospital credentialed health care provider. The clinic is for adult patients, offers only bamlanivimab and estesevimab, administered simultaneously, at this time, and is open Mondays, Tuesdays, Thursdays and Fridays from 7 to 11 a.m.

For Referring Providers – Baltimore Convention Center

To refer a patient for treatment to the Baltimore Convention Center COVID-19 Infusion Center, outpatient providers should complete this Infusion Center online referral form.

The Baltimore Convention Center infusion suite team will review the referral form upon receipt and contact the patient to coordinate services as soon as possible.

The infusion combination therapy, casirivimab and imdevimab, acts similarly to bamlanivimab, with similar inclusion and exclusion criteria. This combination therapy is not offered at our site at this time, but it may be offered in the near future. Both treatments have the same FDA EUA criteria, and have been demonstrated to reduce COVID-19 hospitalization or emergency room visits when administered within 10 days of symptom onset.

Therapy must be ordered for the treatment of mild to moderate COVID-19 in adults and pediatric patients who have positive results of direct SARS-CoV-2 viral testing, are 12 years of age or older, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria:

  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease
  • Are 12–17 years of age AND have a BMI ≥85th percentile for their age and gender based on CDC growth charts: cdc.gov/growthcharts/clinical_charts.htm; OR sickle cell disease; OR congenital or acquired heart disease; OR neurodevelopmental disorders, such as cerebral palsy; OR a medical-related technological dependence, such as tracheostomy gastrostomy or positive pressure ventilation (not related to COVID-19); OR asthma, reactive airway disease or other chronic respiratory disease that requires daily medication for control

These therapies are not authorized for use in patients who:

  • Are hospitalized due to COVID-19
  • Require oxygen therapy due to COVID-19
  • Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity

The allocation methodology is based on duration of symptom onset (longest to be prioritized). There is no further risk stratification based on other clinical characteristics at this point. Which treatment is administered will be decided based on availability and logistics.

There is a chance that a patient’s clinical condition may change in the time between referral and arrival at the infusion center, and the patient may no longer be eligible for this treatment. We urge providers to discuss this with patients, and help manage their expectations.

Referring providers should reference these provider fact sheets:

*The infusion center at the Baltimore Convention Center is jointly operated by Johns Hopkins Medicine and University of Maryland Medical System. The University of Maryland Medical Center’s COVID-19 infusion center website is umms.org/InfusionCenter.

For Referring Providers – Howard County General Hospital (HCGH)

Appointments require a referral from a primary care provider. To refer a patient to HCGH:

  • Primary care providers with access to Epic can place a Future Order for bamlanivimab and etesevimab directly in Epic. View instructions for submitting the infusion referral order in Epic (JHED ID required).

  • Primary care providers without access to Epic should complete the requisition form and submit it by secure* email to hcgh-mab-referral@jhmi.edu (Note*: You must include the word secure in brackets (i.e., [secure]) in the subject line of the email to encrypt it to meet HIPAA requirements).

  • If the patient is a new HCGH / JHM patient, a medical record will need to be created before an appointment can be made. Primary care providers with patients who are new to HCGH / JHM should complete the requisition form and submit it by secure* email to hcgh-mab-referral@jhmi.edu (Note*: You must include the word secure in brackets (i.e., [secure]) in the subject line of the email to encrypt it to meet HIPAA requirements).

Once an order is placed, HCGH Central Scheduling will contact the patient to schedule the appointment and provide instructions for arrival.

The infusion combination therapy, casirivimab and imdevimab, acts similarly to bamlanivimab and etesevimab, with similar inclusion and exclusion criteria. Casirivimab and imdevimab is not offered at our site at this time, but it may be offered in the near future. Both treatments have the same FDA EUA criteria, and have been demonstrated to reduce COVID-19 hospitalization or emergency room visits when administered within 10 days of symptom onset.

Therapy must be ordered for the treatment of mild to moderate COVID-19 in adult patients who have positive results of direct SARS-CoV-2 viral testing, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria:

  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease

These therapies are not authorized for use in patients who:

  • Are hospitalized due to COVID-19
  • Require oxygen therapy due to COVID-19
  • Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity

The allocation methodology is based on duration of symptom onset (longest to be prioritized). There is no further risk stratification based on other clinical characteristics at this point. Which treatment is administered will be decided based on availability and logistics.

There is a chance that a patient’s clinical condition may change in the time between referral and arrival at the infusion center, and the patient may no longer be eligible for this treatment. We urge providers to discuss this with patients and help manage their expectations.

Please refer to the bamlanivimab and etesevimab provider fact sheet and ensure that your patient(s) coming to HCGH for treatment receives the bamlanivimab and etesevimab fact sheet for patients, parents and caregivers prior to the appointment.

For Referring Providers – Sibley Memorial Hospital

To refer a patient to Sibley, complete the requisition form and submit it to the Sibley Department of Pharmacy by email or fax.

  • By secure* email to smh-pharmacistgroup@lists.johnshopkins.edu (Note*: Include [secure] in the subject line of the email to encrypt it to meet HIPAA requirements.)
  • By fax to (202) 537-0072. Please follow your fax with a phone call to the pharmacy department at (202) 537-4171 to ensure prompt attention.

After receiving your requisition form, a pharmacy staff member will contact you/your office regarding approval or denial decision based on drug availability and inclusion criteria. If the patient is a new Sibley patient, a medical record will be created. Appointments will be made on a first-come, first-served basis to ensure equitable and fair distribution. Once the order is placed, a Sibley staff member will contact the patient to coordinate services as soon as possible.

The infusion combination therapy, casirivimab and imdevimab, acts similarly to bamlanivimab, with comparable inclusion and exclusion criteria. This therapy is not offered at our site at this time, but it may be offered in the near future. Sibley Memorial Hospital will notify its credentialed health care providers once it is available. The goal for both therapies, as noted in the FDA EUA, is to prevent COVID-19 disease progression and reduce hospitalization or emergency room visits. It is important to note that these therapies are most effective when administered within 10 days of symptom onset.

Therapy may be ordered for the treatment of mild to moderate COVID-19 in adults patients who have positive results of direct SARS-CoV-2 viral testing, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. Sibley is not administering this therapy to pediatric patients. High risk is defined as patients who meet at least one of the following criteria:

  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease

These therapies are not authorized for use in patients who:

  • Are hospitalized due to COVID-19
  • Require oxygen therapy due to COVID-19
  • Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity

There is a chance that a patient’s clinical condition may change in the time between referral and arrival at the infusion center, and the patient may no longer be eligible for this treatment. We urge providers to discuss this with patients and help manage their expectations.

Please refer to the bamlanivimab and etesevimab provider fact sheet and ensure that your patient(s) coming to Sibley for treatment receives the bamlanivimab and etesevimab fact sheet for patients, parents and caregivers prior to the appointment.

back to top button